Wire · operational-macro
FDA approval, pipeline progress, and strategic buybacks drive a hybrid royalty and R&D model
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 September 2026 · Fusion42 review
FDA approval of zanidatamab and progress in the R&D pipeline position Zymeworks for significant royalty and milestone revenues, supported by strategic buybacks, acquisitions, and global partnerships in a hybrid royalty and R&D business model.
This Wire brief sits within Fusion42's coverage of Biotech, and 1 source has reported it between 14 Sep 2026 and 15 Sep 2026.
◆ ◆ The Wire takeaway
You should reassess your biotech funding strategy as hybrid models blending royalty streams with R&D innovation gain investor interest and strategic weight. This shift opens new routes to capital and reduces reliance on traditional funding rounds.
◆ Coverage
1 source · first reported 14 Sep 2026 · latest 15 Sep 2026
◆ Related on Wire
◆ Topics